Aqneursa (levacetylleucine)

Ataxia-telangiectasia

Also known as IB1001

Manufacturer: IntraBio
Regulatory submission: sNDA submitted March 2026 and approved September 2026
Launch: Commercially available at approval in September 2026
Last updated: October 2, 2026

Section

Product information and disease description Place of product in therapy

Disease description

127 evidence topics · 84 sources

Definition and etiology8 evidence topics · 7 sources
Epidemiology14 evidence topics · 17 sources
Natural history, survival, and mortality25 evidence topics · 28 sources
Pathophysiology10 evidence topics · 7 sources
Diagnosis15 evidence topics · 17 sources
Clinical presentation - signs and symptoms16 evidence topics · 21 sources
Long-term morbidity14 evidence topics · 20 sources
Burden of Ataxia-telangiectasia25 evidence topics · 15 sources